* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour
Dish of the day
Admissions:
Delistings:
What’s baking in the oven? **
Potential**** Initial Public Offerings:
ITF announced:
22nd May: Raspberry Pi announces an intention to float onto the Premium listing segment of the Main Market. Raspberry Pi is a designer and developer of high-performance, low-cost single board computers and compute modules for industrial IoT customers and embedded uses, as well as for enthusiasts and educators, in markets worldwide. The Company is looking to raise $40m, the net proceeds of which will be used by the Company for engineering capital expenditure, to enhance its supply chain resilience and for other general corporate purposes. The Group's revenue was $140.6m, $187.9m and $265.8m and gross profit was $41.9m, $42.3m and $66.0m in the years ended 31 December 2021, 2022, and 2023, respectively.
4th June: Advanced Oxygen Therapy Inc (AOTI): The medical technology group with a proprietary therapy for the reduction in hospitalisations and amputations caused by non-healing wounds, particularly diabetic foot ulcers, announces its Schedule One and expected first day of trading on the AIM market of the 18th June. The Group expects to raise $25m.
Media speculation:
2nd June: Online fashion firm Shein from China is preparing to file a prospectus ahead of a potential London float which could value it around £50bn.
Reverse Takeovers:
Change of Market:
Dual Listing:
Banquet Buffet***
4basebio £14.1 £180.6m (4BB.L)
A technology Company which is a market leader in the development and commercialisation of large scale manufacture of synthetic DNA as well as nanoparticle delivery solutions announces its results for the financial year ended 31 December 2023. Revenue increased to £506k (2022: £268k), the loss before tax increased to £8.35m (2022: £5.93m) and cash and cash equivalents decreased to £3.07m (2022: £4.35m). The overall objective is to continue developing and commercialising the most efficient and highest performant DNA products for each application.
Angle 16p £41.7m (AGL.L)
The liquid biopsy Company with innovative circulating tumour cell diagnostic solutions for use in research, drug development and clinical oncology today announces unaudited preliminary results for the year ended 31 December 2023. Revenues increased to £2.2m (2022: £1.0m), the loss for the year decreased to £20.1m (2022: £21.7m) and cash and cash equivalents decreased to £16.2m (2022: £31.9m). 2024 saw a strong start with product and services customer relationships developing well and a significant expansion of pharma services business. The Company also announces its intention to raise gross proceeds of approximately £8.5m by means of a placing at a price of 15p per share. The Issue Price represents a discount of approximately 16.7%. to the closing mid-market price of 18p per Ordinary Share on 4 June 2024. In addition to the Placing and Subscription, the Company proposes to raise up to a further £2.06m (before expenses) by way of an Open Offer at the Issue Price of 15p. The audited statutory Financial Statements for the year ended 31 December 2023 are expected to be distributed to shareholders no later than 17 June 2024.
Corero Network Security 13.5p £68.7m (CNS.L)
The distributed denial of service (DDoS) protection specialists announce it has secured a $1m three-year contract extension, expanding the current services provided to DigitalOcean Holdings, Inc, a US cloud computing provider. Corero will continue to provide DigitalOcean with its comprehensive SecureWatch Managed Services, reinforcing its trusted position in safeguarding DigitalOcean's extensive network infrastructure. Corero's fully managed solution encompasses configuration optimisation, proactive monitoring, and swift mitigation response to any DDoS incidents and has been tailored to meet DigitalOcean's specific security policies.
European Green Transition 16.15p £23.4m (EGT.L)
A Company developing green economy assets in Europe which aims to capitalise on the opportunity created by the green energy transition announces further results, in addition to the results announced on 15 May 2024, from recent grab samples taken at the Djupedal prospect, the nearby Bersummen area, and the newly identified Stora Lockerum structure, all located within the Olserum Rare Earth Elements (REE) project in south Sweden. High-grade samples of dump material at Djupedal assayed 4.79%, 5.8% and 11.77% TREO (Total Rare Earth Oxides). Encouraging results support the Directors' belief that EGT's fully permitted low-cost drill programme scheduled for H2-2024 could confirm district further project upside, supporting the aim of attracting a partner to fund a larger scale programme.
ImmuPharma 2.475p £10.3m (IMM.L)
The drug discovery and development Company announces its Final Results for the twelve months ended 31 December 2023. Research and development expenses remained constant at £2.0m (2022: £2.0m), the loss for the period decreased to £2.9m (2022: £3.8m) and the cash balance at 31 December 2023 was £0.2m (2022: £0.7m). The board remain focused on bringing two key late stage clinical assets, P140 (Lupuzor) and CIDP, closer to the market, as well as securing partnering deals for earlier stage assets, specifically within anti-infectives program.
M Winkworth 202p £26.1m (WINK.L)
The franchisor of real estate agencies announces the appointments of Tom Fyson and Jonathan Adams as Non-Executive Directors of the Company, and as members of the Audit Committee and Remuneration Committee respectively, with effect from 4 June 2024. The Company also announces that John Nicol, who has been a Non-Executive Director of the Company and a member of the Audit and Remuneration Committees since 10 June 2014, has elected to stand down with effect from 12 September 2024 to pursue his charitable interests.
Mindflair 0.525p £1.4m (MFAI.L)
The Company investing in next-generation technology focused on AI, notes the announcement made by Sure Valley Ventures
regarding the first investment by Sure Valley Ventures III (SVV3) Limited Partnership, in which it has an investment. SVV3 has led a $1.1m funding round for Inspeq AI, a transformative full-stack AI Ops platform, alongside Delta Partners and a number of other leading investors. Inspeq AI aims to become the trusted source of safe and reliable AI development, enhancing generative (Gen) AI application deployment with its comprehensive platform designed for effective and efficient production.
Pantheon Resources 36.55p £345.1m (PANR.L)
The owner of a 100% working interest in the Kodiak and Ahpun oil and gas fields, and the Alaska Gasline Development Corporation (AGDC), a state-owned entity leading the development of the Alaska LNG Project (Alaska LNG) announces that Pantheon's wholly owned subsidiary, Great Bear Pantheon LLC, has entered into a Gas Sales Precedent Agreement (GSPA) with AGDC subsidiary 8 Star Alaska LLC. Alaska LNG is a federally authorised integrated natural gas and LNG export project under development, to deliver natural gas within Alaska and export up to 20m tonnes per annum of Liquified Natural Gas (LNG). AGDC is pursuing an option to phase Alaska LNG by prioritising the in-state pipeline portion of Alaska LNG consisting of the 42-inch pipeline from the North Slope to Southcentral Alaska to provide natural gas to avert the looming energy crisis facing the region.
Ramsdens Holdings 195p £62.2m (RFX.L)
The diversified financial services provider and retailer announces its Interim Results for the six months ended 31 March 2024. Revenue increased 12% to £43.8m (HY 23: £39.0m), profit before tax increased 8% to £4.0m (HY 23: £3.7m) and net assets increased to £47.8m (HY 23: £43.0m). H2 FY24 trading to date is in line with the Board's expectations, with continued positive performances across the Company’s diversified income streams.
STV Group 294p £133.9m (STVG.L)
The media Company announces a trading update. Total Advertising Revenue increased 5% and is expected to be up 15-20% in Q2 driven by Euro 2024. The current orderbook of secured future revenues is £86m. Furthermore, the 3-year cost savings plan is on track to deliver £1.5m this year as guided. STV Studios continues to perform strongly, securing major new orders from Netflix, Sky and Discovery in the first half despite the challenging commissioning environment, and is on track to hit target revenues of £140m in FY26.
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.